Therapeutic Effects of Phosphatidylserine on Functional Recovery After Spinal Cord Injury

Technical Summary: Therapeutic Effects of Phosphatidylserine on Functional Recovery After Spinal Cord Injury

Problem Statement
Spinal cord injury (SCI) results in devastating mortality and morbidity, driven not only by the primary traumatic event but significantly by a secondary injury phase. This secondary phase involves a complex cascade of molecular and cellular events, including oxidative stress, neuroinflammation, glial activation, and apoptotic cell death, which lead to progressive tissue degeneration and long-term functional impairment. Current therapeutic strategies, such as methylprednisolone (MP), have limitations and side effects. There is an urgent need for effective neuroprotective agents that can modulate the inflammatory response and intracellular signaling pathways to preserve tissue integrity and enhance functional recovery. Phosphatidylserine (PS), a critical phospholipid in neuronal membranes with known anti-inflammatory and antioxidant properties, has shown promise in other central nervous system (CNS) disorders but requires further investigation regarding its efficacy and molecular mechanisms in SCI.

Methodology
This study utilized a rat model of contusive SCI to evaluate the therapeutic efficacy of Phosphatidylserine (PS) at varying doses (10, 20, and 40 mg/kg) over a 28-day period.

• Experimental Design: 56 male Sprague–Dawley rats were randomly assigned to six groups: Sham (laminectomy only), SCI + Saline (Control), SCI + Olive Oil (Vehicle), and three PS treatment groups (10, 20, and 40 mg/kg). A positive control group received Methylprednisolone (MP, 30 mg/kg) for 7 days.
• Injury Model: SCI was induced via a T9 laminectomy followed by a severe-to-moderate contusion using an aneurysm clip (110 g for 60 seconds).
• Intervention: PS was dissolved in olive oil and administered via a single intraperitoneal (IP) injection immediately post-surgery.
• Assessments:
  • Behavioral: Locomotor function was assessed using the Basso, Beattie, and Bresnahan (BBB) scale on days 0, 3, 5, 7, 14, 21, and 28. Neuropathic pain (thermal hyperalgesia) was evaluated using the Tail-Flick test on days 0, 7, 14, 21, and 28. Body weight was monitored throughout.
  • Imaging: Magnetic Resonance Imaging (MRI) was performed on day 7 to assess edema and lesion extent.
  • Histopathology: On day 28, spinal cord tissues were analyzed via Hematoxylin and Eosin (H&E) staining. A semi-quantitative scoring system evaluated interstitial hemorrhage, inflammatory cell infiltration, and neuronal vacuolation.
  • Molecular Analysis: Enzyme-Linked Immunosorbent Assay (ELISA) quantified cytokine levels (TNF-α, IFN-γ, IL-10). Western blot analysis assessed the phosphorylation and expression of key signaling proteins: p38 MAPK, ERK1/2, NF-κB (p65), and IκBα.

Key Contributions and Results
The study provides comprehensive evidence that PS treatment mitigates secondary injury and promotes functional recovery in a dose-dependent manner.

1. Functional Recovery and Pain Reduction:

   • Locomotor Function: PS-treated rats showed significant improvements in BBB scores compared to the SCI control group. The 40 mg/kg dose achieved scores above 15 by day 28, indicating near-normal movement patterns, with effects comparable to the MP group.
   • Neuropathic Pain: PS treatment significantly reduced thermal hyperalgesia. The 40 mg/kg group exhibited thermal nociceptive thresholds approaching normal levels, demonstrating a dose-dependent reduction in pain sensitivity.
   • Systemic Health: PS treatment, particularly at 40 mg/kg, significantly attenuated the weight loss typically observed post-SCI, maintaining body weight comparable to the MP group.

2. Structural Preservation:

   • MRI Findings: Day 7 MRI revealed that the 40 mg/kg PS group had a markedly smaller hyperintense signal area (edema) and more defined lesion boundaries compared to the SCI control, suggesting reduced vasogenic edema and preservation of microarchitecture.
   • Histopathology: PS treatment significantly reduced inflammatory infiltration, axonal degeneration, and cystic cavity formation. The 40 mg/kg dose resulted in a pathology score (mean ≈ 1.5) significantly lower than the SCI control (mean ≈ 3.0) and approaching the efficacy of MP (mean ≈ 1.0).

3. Molecular Mechanisms:

   • Cytokine Modulation: PS treatment significantly suppressed pro-inflammatory cytokines TNF-α and IFN-γ while restoring the levels of the anti-inflammatory cytokine IL-10. The anti-inflammatory profile of the 40 mg/kg PS group was statistically comparable to that of the MP group.
   • Signaling Pathway Inhibition: Western blot analysis demonstrated that PS inhibited the phosphorylation of key inflammatory signaling proteins. Specifically, PS reduced the activation of the MAPK and ERK1/2 pathways and prevented the degradation of IκBα, thereby inhibiting the activation of the NF-κB pathway. This suggests PS attenuates the inflammatory signaling cascades that drive secondary injury.

Significance and Claims
The authors claim that Phosphatidylserine represents a promising therapeutic adjunct for SCI. The study concludes that PS exerts its neuroprotective effects through a multi-targeted mechanism: modulating inflammatory responses (suppressing TNF-α/IFN-γ and restoring IL-10) and inhibiting intracellular signaling pathways (MAPK/ERK and NF-κB).

The paper posits that high-dose PS (40 mg/kg) achieves functional and histological outcomes comparable to methylprednisolone, the current pharmacological standard, but potentially with a more favorable safety profile given PS's natural occurrence in neuronal membranes. The authors state that these findings pave the way for future applications of PS as an adjunct to current treatments, instilling optimism for improved SCI management. However, the paper modestly acknowledges limitations, noting that the study focused on acute and subacute outcomes (28 days), and that long-term safety, pharmacokinetic profiling, and human clinical trials are necessary before clinical translation.